ONCY — ONCOLYTICS BIOTECH INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1129928 ·
Last close
$0.81
Market Cap
$96.71M
52W High
$1.19
52W Low
$0.77
ADV30
1,085,050
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -9,281,000 | -9,243,000 | 8,161,000 | 5,493,000 | 13,291,000 |
| Dec 2025 | 0 | — | -9,651,891 | -9,177,897 | 7,582,000 | 5,202,000 | 11,381,000 |
| Sep 2025 | 0 | — | -9,944,315 | -10,346,686 | 10,818,753 | 8,875,157 | 10,736,124 |
| Jun 2025 | 0 | — | -4,169,986 | -4,505,426 | 14,597,143 | 10,688,786 | 10,147,258 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-20,112,000
Investing CF
$-6,000
Financing CF
$14,120,000
CapEx
$-32,678
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.30
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-429,495,000
Inventory
—
Receivables
$573,000
ST Investments
—
EBIT TTM
$-28,656,800
Pretax Income TTM
$-28,622,562
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -28,725,000 | -28,759,000 | 7,582,000 | 11,381,000 | — | -20,112,000 |
| Dec 2024 | 0 | -25,542,000 | -22,794,000 | 13,421,000 | 10,123,000 | — | -19,883,000 |
| Dec 2023 | 0 | -25,471,883 | -20,919,644 | 29,262,777 | 8,485,602 | — | -21,444,294 |
| Dec 2022 | 0 | -19,837,902 | -18,298,703 | 27,508,105 | 7,981,138 | — | -17,208,223 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.26
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RANI | Rani Therapeutics Holdings, Inc. | $93.97M | $0.94 | — |
| PMN | ProMIS Neurosciences Inc. | $92.91M | $10.36 | — |
| RVRC | Revium Rx. | $101.42M | $1.67 | — |
| BMEA | Biomea Fusion, Inc. | $101.94M | $1.41 | — |
| AARD | Aardvark Therapeutics, Inc. | $91.63M | $4.20 | — |
News headlines (Yahoo Finance, 1h cache)
From Ambrx to Oncolytics: Why Jared Kelly Believes the Market May Be Missing the Bigger Oncology Story
2026-05-26 13:00 · Yahoo
Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors
2026-05-22 13:00 · Yahoo
ONCY: Aligns with FDA on Pivotal Trial for Pelareorep in Anal Cancer
2026-05-19 11:35 · Yahoo
Oncolytics Biotech Reports Data in Colorectal Cancer Study
2026-05-06 22:48 · Yahoo
Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer
2026-05-04 13:00 · Yahoo
CEO Chat with Jared Kelly, CEO of Oncolytics Biotech
2026-05-01 10:48 · Yahoo
ONCY: Initiating Coverage of Oncolytics Biotech; A Focused Path to Unlocking the Potential of Pelareorep
2026-04-07 09:36 · Yahoo
Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer
2026-04-06 13:00 · Yahoo
Oncolytics Biotech’s Nevada Move Resets Capital Access And Dilution Trade Off
2026-04-01 20:07 · Yahoo
Oncolytics Biotech® Completes Domicile Change to the United States
2026-04-01 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.